References
- Livermore D. Quinupristin/dalfopristin and linezolid: where, when, which and whether to use? J Antimicrob Chemother 2000; 46: 347–50.
- Diekema DJ, Jones RN. Oxazolidinones antibiotics. Lancet 2001; 358: 1975–82.
- European Committee on Antimicrobial Susceptibiity Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Linezolid breakpoints. Clin Microbiol Infect 2001; 7: 283–4.
- Thielman NM. Antibiotic-associated colitis. In: Mandell GL, Bennett JE, Dolin R. Principles and practice of infectious diseases. Churchill-Livingstone, Philadelphia, PA, 2000: 1111-1125.
- Fekety R. Guidelines for the diagnosis and management of Clostridium difficile associated diarrhea and colitis. Am J Gastroenterol 1997; 92: 739–50.
- Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva JJr. Clostridium difficile associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995; 16: 459–77.
- Lode H, Von der Hoh N, Ziege S, Borner K, Nord CE. Ecological effects of linezolid versus amoxicillin/clavulanic acid on the normal intestinal microflora. Scand J Infect Dis 2001; 33: 899–903.
- Ackerman G, Adler D, Rodloff AC. In vitro activity of linezolid against Clostridium difficile. J Antimicrob Chemother 2003; 51: 743–4.
- Goldstein EJ, Citron DM, Merriam CV, Warren Y, Tyrrell K, Fernandez HT. In vitro activities of dalbavancin and nine comparator agents against anaerobic gram positive species and Corynebacteria. Antimicrob Agents Chemother 2003; 47: 1968–71.